Iovance Biotherapeutics is trading 5% up at $8.39, apparently benefiting from continued biotechnology enthusiasm after Moderna and Merck reported positive Phase 3 melanoma-vaccine results.
- Extended its 13.66% gain on August 19.
- No new company-specific announcement was identified on August 20.
- Recent strength also follows record second-quarter revenue of approximately $99 million.